JMP Securities Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $22.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target cut by investment analysts at JMP Securities from $23.00 to $22.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target would suggest a potential upside of 72.41% from the stock’s previous close.

Several other brokerages have also issued reports on ENTA. JPMorgan Chase & Co. dropped their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. StockNews.com cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Stock Down 2.6 %

Shares of ENTA opened at $12.76 on Tuesday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $28.25. The company has a market cap of $269.95 million, a PE ratio of -2.04 and a beta of 0.54. The business has a fifty day moving average of $14.88 and a 200 day moving average of $12.08.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The firm had revenue of $18.00 million during the quarter, compared to the consensus estimate of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. As a group, research analysts anticipate that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ENTA. Nisa Investment Advisors LLC grew its position in shares of Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,281 shares in the last quarter. Strs Ohio grew its holdings in Enanta Pharmaceuticals by 20.6% during the 4th quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 3,200 shares in the last quarter. Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals during the 3rd quarter worth about $57,000. Quantbot Technologies LP increased its position in Enanta Pharmaceuticals by 2,300.0% during the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares during the period. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $113,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.